Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Neurochem. 2016 Dec 20;140(2):334–346. doi: 10.1111/jnc.13892

Figure 1. Higher lactide content facilitates release of lovastatin from encapsulated lactide:glycolide co-polymer.

Figure 1

(A) Representative composite HPLC chromatograms showing inactive lovastatin prodrug (red trace, retention time 8.5 min.) extracted from lovastatin-encapsulating nanoparticles or active lovastatin hydroxy acid recovered from dialysate (green trace, retention time 5.6 min.). For comparison, co-migration with authentic standards (blue trace, lovastatin prodrug; black trace, lovastatin hydroxy acid) are shown. (B) Time-dependent cumulative release of lovastatin hydroxy acid following static dialysis of empty- or lovastatin-encapsulating PLGA nanoparticles as a function of lactide:glycolide co-polymer composition. Release from 25% w/w drug loaded (DL) 85:15 co-polymer is shown for comparison. Data shown are the mean ± SEM.